Literature DB >> 16600625

The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent.

Marc Kirschner1, Val Monrose, Maciej Paluch, Nipa Techodamrongsin, Axel Rethwilm, John P Moore.   

Abstract

Trimeric HIV-1 envelope glycoproteins (Env) are now being evaluated instead of monomeric gp120 as vaccine antigens because they mimic more closely the spikes expressed on the surface of virions. Thus, it can be argued that trimers have a more native structure than gp120, so might be superior at raising neutralizing antibodies. One approach to making Env trimers is to ensure that they are cleaved at the gp120-gp41 border, but stabilized by other, engineered substitutions such as intra-subunit disulfide bonds (SOS and SOSIP gp140 proteins). However, the production of properly folded, cleaved trimers is complicated by the requirement for co-expression of the exogenous protease furin, to facilitate the efficient processing oft the gp120-gp41 cleavage site. Also, yields of purified trimeric SOSIP gp140 proteins are usually moderate and for scale-up procedures the cost of transfection reagents becomes an important economical factor. Here, we assess the optimal culture conditions for the transient expression of these complex proteins. We found that the use of linear polyethylenimine 25 kDa (PEI25k) as a transfection aid was a cost-efficient, economical alternative to several commercially available products. By using PEI25k and an optimized plasmid:furin ratio, we could express proteolytically mature, trimeric Env vaccine antigens at levels high enough for use in immunization or structural studies. We also show that the same transfection method can be used to generate infectious pseudoviruses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16600625     DOI: 10.1016/j.pep.2006.02.017

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  30 in total

1.  A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses.

Authors:  Thijs van Montfort; Mark Melchers; Gözde Isik; Sergey Menis; Po-Ssu Huang; Katie Matthews; Elizabeth Michael; Ben Berkhout; William R Schief; John P Moore; Rogier W Sanders
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

2.  Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.

Authors:  Ilja Bontjer; Mark Melchers; Dirk Eggink; Kathryn David; John P Moore; Ben Berkhout; Rogier W Sanders
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

3.  Genetic variations in the C epsilon mX domain of human membrane-bound IgE.

Authors:  Lei Wan; Jiun-Bo Chen; Hsih Hsin Chen; Janice Huang; Hui-Ming Yu; Shue-Fen Luo; Fuu Jen Tsai; Tse Wen Chang
Journal:  Immunogenetics       Date:  2010-03-24       Impact factor: 2.846

4.  HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation.

Authors:  Thijs van Montfort; Dirk Eggink; Maikel Boot; Michael Tuen; Catarina E Hioe; Ben Berkhout; Rogier W Sanders
Journal:  J Immunol       Date:  2011-09-28       Impact factor: 5.422

5.  Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.

Authors:  Ralph Pantophlet; Rowena O Aguilar-Sino; Terri Wrin; Lisa A Cavacini; Dennis R Burton
Journal:  Virology       Date:  2007-04-06       Impact factor: 3.616

6.  Efficient recovery of high-affinity antibodies from a single-chain Fab yeast display library.

Authors:  Laura M Walker; Diana R Bowley; Dennis R Burton
Journal:  J Mol Biol       Date:  2009-04-16       Impact factor: 5.469

7.  Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.

Authors:  Yun Kenneth Kang; Sofija Andjelic; James M Binley; Emma T Crooks; Michael Franti; Sai Prasad N Iyer; Gerald P Donovan; Antu K Dey; Ping Zhu; Kenneth H Roux; Robert J Durso; Thomas F Parsons; Paul J Maddon; John P Moore; William C Olson
Journal:  Vaccine       Date:  2009-06-28       Impact factor: 3.641

8.  Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.

Authors:  Emily J Platt; Michelle M Gomes; David Kabat
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

9.  A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.

Authors:  Pavel Pugach; Gabriel Ozorowski; Albert Cupo; Rajesh Ringe; Anila Yasmeen; Natalia de Val; Ronald Derking; Helen J Kim; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Jean-Philippe Julien; Dennis R Burton; Ian A Wilson; Rogier W Sanders; P J Klasse; Andrew B Ward; John P Moore
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

10.  Analysis of a Subacute Sclerosing Panencephalitis Genotype B3 Virus from the 2009-2010 South African Measles Epidemic Shows That Hyperfusogenic F Proteins Contribute to Measles Virus Infection in the Brain.

Authors:  Fabrizio Angius; Heidi Smuts; Ksenia Rybkina; Debora Stelitano; Brian Eley; Jo Wilmshurst; Marion Ferren; Alexandre Lalande; Cyrille Mathieu; Anne Moscona; Branka Horvat; Takao Hashiguchi; Matteo Porotto; Diana Hardie
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.